Matrix Bio to present in July

PRESS RELEASE – July 17, 2013, 10:00 a.m. EDT

Matrix-Bio’s CEO to Present at New Mexico Angels’ July Investors Showcase

FORT WAYNE, Ind., Jul 17, 2013 (BUSINESS WIRE) — Matrix-Bio Chief Executive Officer Eric Beier, M.D., M.B.A., will be a featured presenter at the New Mexico Angels’ July Investors Showcase in Albuquerque and Santa Fe, New Mexico, held July 24 and 25 respectively. Matrix-Bio is a cancer metabolomics diagnostics company and is developing diagnostic tests that use metabolite profiling to detect cancer earlier and with greater accuracy than current tests.

Founded in 1999, the New Mexico Angels is among the Southwest’s premier angel investing groups. Led by President John Chavez, the New Mexico Angels invest primarily in seed or early-stage companies in the Southwest, focusing on accelerating market leadership and securing results for members. The New Mexico Angels are early investors in Matrix-Bio, having funded two rounds in the cancer metabolomics diagnostic company since 2011.

Matrix-Bio is a pioneer in the emerging field of metabolomics-based cancer diagnostics. Beier will provide New Mexico Angels investors with an update on the global licensing agreement Matrix-Bio signed with Quest Diagnostics for the development of a clinical lab-developed test using metabolite profiling to detect breast cancer recurrence. Matrix-Bio’s VeraMarker(TM) BCR test detects the recurrence of breast cancer with twice the accuracy and 11 months earlier than the current CA 27-29 test, of which three million are performed in the United States annually.

Beier is seeking additional investment from the New Mexico Angels for the development of new cancer diagnostic and cancer treatment monitoring tests, which can provide for tailoring of chemotherapy treatment and dosing to individual patients. In May, Matrix-Bio licensed metabolite biomarker technology from the Purdue Research Foundation to evaluate the commercial potential of diagnostic tests for esophageal, liver, pancreatic and colon cancer; liver cancer in hepatitis C patients; and predicting preoperative chemotherapy effectiveness for breast cancer treatment.

Commenting on Matrix-Bio’s visit, Chavez said, “We are pleased to have Dr. Eric Beier present at our meetings. As early stage investors in this exciting blood serum-based cancer diagnostics technology, the New Mexico Angels are interested in the company’s progress and opportunities for further investment.”

Metabolite-profiling technology is gaining momentum in cancer diagnostics. Metabolomics-based tests identify the unique metabolite signature of cancer cells in blood serum samples, supporting early, more accurate cancer detection.

Details on the New Mexico Angels Investor Showcase meetings July 24 and 25 at www.nmangels.com.

About Matrix-Bio

Matrix-Bio, Inc. is focused on the development and commercialization of metabolite profiling-based blood tests for early cancer detection, recurrence detection, and therapy monitoring that offer greater accuracy, convenience, and lower cost than current testing methodologies. Visit www.matrix-bio.com. Contact mlux@luxandassociates.com.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130717005721r1&sid=cmtx6&distro=nx

SOURCE: Matrix-Bio, Inc.

Comments are closed.


Previous « A Billion Here, A Billion There | NMA Funds Tyrosine Pharmaceuticals’ Stroke Therapy » Next
Join Our Email List

Copyright 2017 New Mexico Angels · RSS Feed · Carbon Neutral Green Hosting Log in